T he high rate of residual cardiovascular disease (CVD) events occurring among individuals treated with statins (approximately 1 in 7 statin-treated patients during a 5-year period) 1, 2 has driven interest in therapeutic interventions targeted at reducing residual risk by modulating high-density lipoprotein (HDL). Major efforts have been directed in translational experimental laboratories and large-scale trials using agents that raise HDL cholesterol (HDL-C). Recent failures of drugs that raised HDL-C without reducing events [3] [4] [5] or atherosclerosis 6 may be in part attributable to the limitations of the specific agents tested or the trial designs. This, in addition to recognizing that certain polymorphisms in the hepatic and endothelial lipase genes resulting in low or high HDL-C may not correspond to expected differences in risk, 7, 8 have raised the possibility that HDL-C may not be the best clinical measure of HDL.
B, non-HDL-C, and high-sensitivity C-reactive protein (hsCRP). 12, 13 Chemically measured HDL-C, which evaluates the cholesterol carried by HDL particles, may not fully capture HDL-related cardioprotection. It has been hypothesized that alternative indices of HDL, such as HDL function, size, or the concentration (number) of HDL particles (HDL-P), may be better clinical markers of HDL. HDL-C is carried within lipoprotein particles that are particularly heterogeneous, varying in size, density, charge, lipid and proteomic composition, apolipoproteins, metabolism, and function.
14 Very little is known about the impact of statin therapy on measures of HDL other than HDL-C.
After the JUPITER trial completion but before obtaining the nuclear magnetic resonance (NMR) HDL measurements, we prespecified the hypothesis that the residual risk of CVD may be better explained by HDL-P in comparison with HDL-C. We aimed to evaluate this in JUPITER, because the trial provides a unique opportunity to address whether or not residual risk is related to HDL measures after random allocation to potent statin therapy in a primary prevention population that achieved very low LDL-C levels.
Methods

Study Population
The JUPITER trial randomly assigned 17 802 asymptomatic women ≥60 years and men ≥50 years without a previous history of CVD or diabetes mellitus who had LDL-C <130 mg/dL, hsCRP ≥2.0 mg/L, and triglycerides <500 mg/dL, as previously described. 15 Exclusion criteria included previous or current use of lipid-lowering therapy. Study participants were asked to provide a blood sample before randomization and after 1 year; 11 953 provided samples both at baseline and 1 year, and these were stored in liquid nitrogen. After trial completion, HDL size and HDL-P were measured by proton NMR spectroscopy on these samples. A total of 10 886 had complete baseline values of the HDL measures, and 10 046 had both baseline and 1-year measurements.
Laboratory Measurements
Lipid measurements were performed on fasting samples in a central laboratory. 12 Chemically measured HDL-C was assayed in the resulting supernatant after heparin-manganese precipitation of apolipoprotein B-containing proteins. Triglycerides were measured with an enzymatic hydrolysis procedure to obtain a colorimetric end point triglyceride value. LDL-C concentrations were calculated by the Friedewald equation when triglycerides were <400 mg/dL, and measured by ultracentrifugation when triglycerides were ≥400 mg/dL. 16 ApoA-I was measured by immunonephelometry by using a Behring nephelometric assay (Marburg, Germany).
Samples for lipoprotein particle analysis by NMR spectroscopy were shipped on dry ice to LipoScience, Inc (Raleigh, NC) where HDL-P and HDL size were measured. HDL-P is the sum of the particle concentrations of the HDL subclasses, which were quantified based on particle size by using the amplitudes of their lipid methyl group NMR signals. 17, 18 Mean HDL size was calculated as the weighted average of the HDL subclasses.
Outcomes
The primary end point of JUPITER was a composite CVD end point, defined as first myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization, or cardiovascular death. We also examined the expanded end point of CVD and allcause death as we had previously done in relation to HDL-C and other lipids. 12 Follow-up included structured interviews assessing outcomes. All reported primary end points were adjudicated by an independent end point committee blinded to randomized treatment assignment. CVD events were confirmed according to standard criteria.
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Statistical Analyses
Statistical analyses were performed with STATA software, version 10.1. Medians, 25th, and 75th percentiles were calculated for continuous variables. Spearman correlation coefficients were used as nonparametric measures of association for HDL measures. Change from baseline to on-treatment levels were compared statistically with Wilcoxon signed rank test, and change among the placebo group versus rosuvastatin group was compared with the Wilcoxon rank sum test. Statistical tests for outcomes were performed according to the treatment to which participants were randomly assigned. The exposure time was calculated as the time from randomization to occurrence of the primary end point or the date of death, last study visit, withdrawal, loss to follow-up, or trial completion, whichever came first. Absolute event rates were calculated per 100 personyears. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs). All regression analyses were risk factor-adjusted for age, sex, smoking status, systolic blood pressure, body mass index, fasting glucose, LDL-C, triglycerides (natural log-transformed), and family history of premature atherosclerosis. Each HDL measure was examined in tertiles and as continuous variables (per 1 standard deviation [1 SD]). To allow for comparison across groups, the HRs were calculated by using the SDs of baseline levels. Tertile cut points were calculated across both treatment arms. The likelihood ratio χ 2 statistic and corresponding P value were used to evaluate the additional predictive value of HDL-P or HDL size over a model with risk factors alone or with HDL-C. The probability value for linear trend was obtained by using the median value for each tertile. Results were not adjusted for multiple comparisons, and a 2-tailed P value of <0.05 was considered to indicate statistical significance.
Results
Baseline characteristics for individuals with NMR HDL measurements (available for analysis) were generally similar to the overall JUPITER population (Table 1) . 15 The current study, however, had more white participants. Median baseline HDL-C, apoA-I, LDL-C, and hsCRP were 49 mg/dL (1.27 mmol/L), 164 mg/dL, 109 mg/dL (2.82 mmol/L), and 4.1 mg/L, respectively, almost identical to the JUPITER population as a whole, 15 and similar to the individuals who were not in the current study. Median HDL size (9.0 nm) and HDL-P (32.3 µmol/L) were consistent with values seen from other asymptomatic populations.
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Reproducibility and Correlations
Among the placebo-treated individuals, Spearman selfcorrelation coefficients showed high agreement over time between baseline and 1-year values for HDL-C, apoA-I, HDL size, and HDL-P (r=0.85, 0.75, 0.80, and 0.73, respectively; all P<0.0001). These compared favorably with coefficients for total cholesterol (r=0.62), LDL-C (r=0.55), and triglycerides (r=0.74).
HDL-P correlated only moderately with HDL-C at baseline (r=0.55, P<0.0001; Table I 
Changes With Rosuvastatin
Random allocation to rosuvastatin 20 mg/d decreased LDL-C by 51 mg/dL (49%), and increased HDL-C by 3 mg/dL and apoA-I by 3 mg/dL, similar to the main trial findings (all P<0.0001; Table 2 ). 15 Further, HDL size was increased by 0.1 nm, and HDL-P by 1.3 µmol/L (P<0.0001 for all). There was a greater proportional HDL-C increase (6.1%) with statin therapy from baseline to 1 year than was seen for apoA-I (2.1%) or HDL-P (3.8%). HDL size also increased with statin therapy, but to a lesser extent (1.2%).
Association With CVD Events
During a median follow-up of 2.0 years (maximum, 5.0), a total of 234 primary events occurred among the 10 886 individuals. The primary end point was reduced with rosuvastatin 20 mg versus placebo by 43% (P<0.001), almost identical to the overall JUPITER results (44%). 15 Table 3 shows crude incidence CVD rates and risk factor-adjusted associations for baseline HDL measures (examined in tertiles and per 1 SD).
Among placebo-allocated individuals, generally similar inverse associations were obtained for baseline HDL-C, apoA-I, and HDL-P with CVD, whereas baseline HDL size showed no statistically significant association with CVD. Among rosuvastatin-allocated individuals, no statistically significant association was seen with CVD in relation to baseline HDL-C (adjusted HR, 0.96; 95% CI, 0.72-1.29 per 1 SD of 15.3 mg/dL), apoA-I (0.84; 95% CI, 0.65-1.10 per 30.2 mg/dL), or size (1.07; 95% CI, 0.82-1.39 per 0.52 nm), whereas baseline HDL-P had a statistically significant association (0.78; 95% CI, 0.61-0.99 per 6.32 µmol/L).
On-placebo (year 1) levels of HDL-C, apoA-I, and HDL-P also had inverse association with CVD (Table 4) , which was not seen for HDL size. Among rosuvastatin-allocated individuals, on-treatment HDL-P had a statistically significant and somewhat stronger association with CVD (0.73, 0.57-0.93; P=0.01) than HDL-C (0.82, 0.63-1.08; P=0.16) or apoA-I (0.86, 0.67-1.10; P=0.22). The likelihood ratio χ 2 probability value of 0.01 indicated added predictive value of on-treatment HDL-P to standard risk factors. In fully adjusted models, the CHD indicates coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HDL-P, high-density lipoprotein particle number; HR, hazard ratio; LDL, low-density lipoprotein; LRT, likelihood-ratio test; and SD, standard deviation.
*Likelihood ratio χ 2 comparing a model that adds either HDL-C, HDL size, or HDL-P to the basic risk factors of age, sex, race, smoking, systolic blood pressure, body mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD.
†Incidence per 100 person-years ‡Cox proportional hazards ratios were adjusted for age, sex, race, smoking, systolic blood pressure, body mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD. SDs were 15.3 mg/dL for HDL-C, 30.2 mg/dL for apolipoprotein A-I, 0.52 nm for HDL size, and 6.32 μmol/L for HDL-P.
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Additional Analyses
Generally stronger associations were obtained for HDL-P and apoA-I when examined in relation to the expanded secondary end point of CVD and death (330 events, Tables II and III in (Table III in the online-only Data Supplement). There was a suggestion that greater HDL size may be associated with increased risk of CVD or death, although this did not reach statistical significance (P=0.09).
Overall, similar patterns of association were seen for women and men (all P interaction >0.05). Further adjustment for hsCRP and LDL particle concentration did not alter the association of HDL-P with CVD. On-treatment HDL-P remained significantly associated with CVD among the 3664 statin-allocated individuals (50 CVD events) with ontreatment LDL-C ≤70 mg/dL (adjusted HR per 1 SD 0.70; 95% CI, 0.51-0.95; P=0.02, P interaction =0.71). Similar results were obtained among the subgroup with on-treatment apolipoprotein B ≤80 mg/dL (0.73; 95% CI, 0.55-0.97; P=0.03, P interaction =0.85).
Analyses Combining HDL Measures
To further address biological relationships between the HDL measures, we repeated analyses adjusting for risk factors plus 2 HDL measures at a time, using the likelihood ratio χ 2 statistic and corresponding P value to assess for statistical significance. For incident CVD (Table 5 ) and the combined end point of CVD and death (Table IV in CHD indicates coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HDL-P, high-density lipoprotein particle number; HR, hazard ratio; LDL, low-density lipoprotein; LRT, likelihood-ratio test; and SD, standard deviation. *Likelihood ratio χ 2 comparing a model that adds either HDL-C, HDL size, or HDL-P to the basic risk factors of age, sex, race, smoking, systolic blood pressure, body mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD.
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By contrast, after additionally adjusting for HDL-P, there was no statistically significant association for HDL-C with CVD or the combined end point of CVD and death. However, HDL-C was generally inversely associated with risk in models that additionally adjusted for HDL size. Finally, HDL size was not significantly associated with CVD after adjustment for HDL-C or HDL-P. However, for the combined end point of CVD and death (Table IV in the online-only Data Supplement), HDL size became positively and statistically significantly associated in most models that adjusted for HDL-C or HDL-P.
Discussion
Among placebo-allocated individuals in JUPITER, ontreatment HDL-C, apoA-I, and HDL-P had similar inverse associations with CVD. Among rosuvastatin-allocated individuals in JUPITER, on-treatment HDL-P had a statistically significant and somewhat stronger association with CVD than HDL-C or apoA-I. This study suggests that HDL-P may be a better marker of residual risk than HDL-C or apoA-I among individuals treated to very low LDL-C levels with potent statin therapy. HDL size was not associated with residual vascular risk or with risk in the absence of statin therapy. However, after additionally adjusting for HDL-C or HDL-P, larger HDL size was associated with increased risk for the combined end point of CVD and all-cause death.
Because HDL particles are quite heterogeneous, and because their functions cannot be inferred from the plasma concentration of chemically measured HDL-C, interest has focused recently on measuring HDL-P, HDL size, and various HDL functions.
14,20 HDL-C is correlated with other HDL parameters such as size and HDL-P, but the relationships are complex. 21 The association of HDL-C with CVD is influenced by metabolic relationships with insulin resistance, abdominal obesity, inflammation, and atherogenic lipoproteins. 21 By contrast, HDL-P appears to be much less correlated with these factors. 19 Furthermore, HDL-P may reflect greater reverse cholesterol transport capacity, 22 and other functional properties, such as antioxidant capacity, more closely than HDL-C. 23 Both niacin and cholesteryl ester transfer protein inhibitors raise HDL-C by increasing HDL size much more than their effect on increasing the number of HDL particles. CHD indicates coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HDL-P, high-density lipoprotein particle number; HR, hazard ratio; LDL, low-density lipoprotein; LRT, likelihood-ratio test; and SD, standard deviation.
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*Cox proportional hazard regression models included 2 HDL measures together with age, sex, race, smoking, systolic blood pressure, body mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD. SDs were 15.3 mg/dL for HDL-C, 30.2 mg/dL for apolipoprotein A-I, 0.52 nm for HDL size, and 6.32 μmol/L for HDL-P.
†The likelihood ratio χ 2 P value for adding the corresponding HDL measure to a model with the other HDL measure. All models also adjusted for the basic risk factors of age, sex, race, smoking, systolic blood pressure, body mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD. by guest on April 29, 2017 http://circ.ahajournals.org/ Downloaded from Although our study was observational and hypothesis generating, its findings suggest that the number of HDL particles 29 may matter more than the size of the particle or the level of HDL-C as a determinant of residual risk among statin-treated individuals. 30 Future studies are needed to examine the various functional properties of HDL in relation to HDL-P, HDL size, and other measures of HDL, and how these are impacted by therapies targeting HDL. 31 Previous epidemiological studies comparing HDL-P with HDL-C are few in number, have not addressed residual risk on a background of potent statin therapy, and have sometimes provided conflicting results. In the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study, HDL-P was inversely associated with CVD, 23 whereas HDL-C and HDL size appeared to confer risk at very high values after adjusting for apolipoproteins B and A-I, 32 consistent with our findings. Among multiethnic individuals, we have previously shown that HDL-P was more closely related to subclinical atherosclerosis and coronary events than HDL-C, 19, 33 and that very high HDL-C may confer increased risk after adjusting for HDL-P and risk factors. 19 Inverse associations of HDL-P with coronary death were also seen in a small case-control study among men with the metabolic syndrome. 34 However, in the Women's Health Study, HDL-P was not associated with incident CVD events among healthy lowrisk women, in contrast with inverse associations seen for HDL size and HDL-C. 35 None of these previous populationbased studies evaluated residual risk on statin therapy.
To our knowledge, this is the first direct comparison of HDL-C, apoA-I, HDL-P, and HDL size in relation to residual risk in a population whose LDL-C has been reduced to contemporary standards with potent statin therapy. This is particularly relevant because the HDL-modifying drugs now under investigation are expected to be used in the clinical setting of individuals with low LDL-C levels on potent statins. In this regard, data evaluating residual risk in relation to onstatin HDL-C, HDL-P, and HDL size are limited to a post hoc investigation of the MRC/BHF Heart Protection Study. In that secondary prevention setting evaluating simvastatin, both HDL-C and HDL-P were inversely associated with residual risk.
36 HDL size carried increased risk of other cardiac events (mostly heart failure) after adjusting for HDL-P. The average on-statin LDL-C in the Heart Protection Study was 89 mg/dL, 37 whereas that in JUPITER was substantially lower (54 mg/dL). Finally, in the recent dal-OUTCOMES trial where dalcetrapib was given on a background of statin treatment, baseline HDL-C did not predict risk, although HDL-P and HDL size were not evaluated. 5 Strengths of this study include the large number of individuals with HDL measures assessed both at baseline and on-treatment, the random allocation of a potent statin versus placebo, and the detailed information on cardiovascular risk factors and outcomes. The present study also has potential limitations. In particular, JUPITER excluded individuals with known CVD, diabetes mellitus, high LDL-C, or high triglycerides. Further, the median HDL-C in JUPITER was 49 mg/dL and the expected increase in HDL-C with rosuvastatin was less than may have been anticipated. Thus, it is uncertain if our data would generalize to individuals who do not meet the current study's inclusion or exclusion criteria. This study was conducted after trial completion, but before obtaining the NMR measurements we had a prespecified protocol for this study, including the hypothesis that the residual risk of CVD may be better explained by HDL-P than by HDL-C. This study was limited to HDL measurements obtained by NMR; other technologies were not examined. 14, 20, 28 Finally, as shown by the significant findings in this study for on-treatment HDL-P, and our previous significant findings for on-treatment LDL-C, non-HDL-C, apolipoprotein B, and hsCRP, we had adequate power to detect true patterns of residual risk in both randomization groups. However, we are unable to rule out a possible association for HDL-C and apoA-I with residual risk because of the relatively small number of events in the rosuvastatin arm. Finally, our results should be viewed as hypothesis generating and will require further evaluation in other studies.
In conclusion, this study provides evidence that the number of HDL particles may be a better marker of residual risk than HDL-C or apoA-I. This has potential implications for evaluating therapeutic interventions targeting HDL in the era of potent LDL-C lowering with statin therapy.
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CLINICAL PERSPECTIVE
Chemically measured high-density lipoprotein cholesterol (HDL-C) may not be the best clinical measure of HDL. Little is known about alternative HDL measures such as HDL size or particle number (HDL-P) as determinants of residual risk after potent statin therapy. In JUPITER, HDL size and HDL-P were measured by nuclear magnetic resonance spectroscopy, and HDL-C and apolipoprotein A-I (apoA-I) were chemically assayed in 10 886 participants without cardiovascular disease or diabetes mellitus before and after random allocation to rosuvastatin 20 mg/d or placebo. Median follow-up was 2 years. At baseline, HDL-P correlated moderately with HDL-C (r=0.55) but more strongly with apoA-I (0.69). HDL size showed greater correlation with HDL-C (r=0.65) than with apoA-I (r=0.56), and much less with HDL-P (r=0.22). Among placebo-allocated individuals, on-treatment HDL-C, apoA-I, and HDL-P had similar inverse associations with cardiovascular disease, whereas HDL size was not associated with cardiovascular disease. Among rosuvastatin-allocated individuals in JUPITER, on-treatment HDL-P had a statistically significant and somewhat stronger association with residual vascular risk (adjusted hazard ratio, 0.72; 95% confidence interval, 0. ♯ Likelihood ratio chi2 comparing a model that adds either HDL-C, HDL size, or HDL-P to the basic risk factors of age, sex, race, smoking, systolic blood pressure, body-mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD.
Supplemental ♯ Likelihood ratio chi2 comparing a model that adds either HDL-C, HDL size, or HDL-P to the basic risk factors of age, sex, race, smoking, systolic blood pressure, body-mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD.
